新型超声造影剂BR55在实体肿瘤诊断和治疗中的研究进展  

Advances of New Ultrasound Contrast Agent BR55 in the Diagnosis and Treatment of Solid Tumors

作　　者：李静波 朱嘉宁 张颖 李秋洋[2] 罗渝昆[2] LI Jingbo;ZHU Jianing;ZHANG Ying;LI Qiuyang;LUO Yukun(Department of Ultrasound Diagnosis,First Medical Center,PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军医学院,北京100853 [2]解放军总医院第一医学中心超声诊断科,北京100853

出　　处：《中国医学影像学杂志》2022年第12期1301-1303,1308,共4页Chinese Journal of Medical Imaging

基　　金：国家自然科学基金(81971635);国家自然科学基金(81801698);后勤科研项目(21BJZ13)。

摘　　要：恶性肿瘤的早期诊断和治疗可以显著改善患者预后,早期监测抗肿瘤药物效能对评估治疗效果具有重要作用。随着超声分子影像学和超声造影技术的不断发展,靶向超声造影技术的应用为肿瘤性病变的早期检测及监测提供新的思路和方法。与正常组织相比,血管内皮生长因子受体-2在恶性肿瘤中的表达明显提高,作为特异性靶向血管内皮生长因子受体-2的超声造影剂BR55可以提高肿瘤的检测和抗肿瘤药物的监测能力。本文拟对靶向造影剂BR55在诊断和治疗肿瘤中的应用进行综述。Malignant tumor is the main cause of death in the world. Early diagnosis and treatment can significantly improve the prognosis.Meanwhile, early monitoring of antineoplastic drugs plays a significant role in evaluating the efficacy of treatment. The advancement of molecular ultrasound imaging and contrast-enhanced ultrasound has provided new methods to the application of targeted contrast-enhanced ultrasound for early detection and monitoring of neoplastic lesions. Compared with normal tissue, vascular endothelial growth factor receptor 2expression is significantly increased in malignant tumors, and BR55 can be used as an ultrasound contrast agent specifically targeting vascular endothelial growth factor receptor 2 for imaging of focal vascular endothelial cells. BR55 can improve the detection of tumors and the monitoring of antiangiogenic drugs. This article reviews the application of targeted contrast agent BR55 in the diagnosis and treatment of tumors.

关 键 词：超声分子影像 超声造影 BR55 血管内皮生长因子受体-2 肿瘤 综述 

分 类 号：R73[医药卫生—肿瘤] R445.1[医药卫生—临床医学]